A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Asthma

Interventions

DRUG

SHR-1905

subcutaneous

DRUG

placebo

subcutaneous ,placebo

Trial Locations (1)

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY